Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K D Friedman

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 13, 2026
Mucosal Bleeding in a Newborn With Low Factor VIII Activity: An Unusual Combination of Type 2A and Type 2N von Willebrand DiseaseGianna G Valenti, A P Miller, A C Weyand, et al.
The Journal of Biological Chemistry|October 15, 1991
Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand diseaseP A Kroner, K D Friedman, S A Fahs, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 1, 1988
Protein C deficiency. A cause of unusual or unexplained thrombosisD F Tollefson, K D Friedman, R A Marlar, et al.
The Journal of Molecular Diagnostics : JMD|March 29, 2001
A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assayM Ledford, K D Friedman, M J Hessner, et al.
Blood|August 1, 1988
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activityJ Owen, K D Friedman, B A Grossman, et al.
The Journal of Clinical Investigation|June 1, 1987
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activatorJ Owen, K D Friedman, B A Grossman, et al.
Clinical Chemistry|October 24, 2001
Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assayM J Hessner, K D Friedman, K V Voelkerding, et al.
Thrombosis and Haemostasis|June 12, 1999
Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCRM J Hessner, R A Luhm, S L Pearson, et al.
British Journal of Haematology|August 12, 1999
Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriersM J Hessner, D M Dinauer, R A Luhm, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 4, 2014
Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472HJ C Francis, S K Hui, D Mahoney, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 13, 2026
Mucosal Bleeding in a Newborn With Low Factor VIII Activity: An Unusual Combination of Type 2A and Type 2N von Willebrand DiseaseGianna G Valenti, A P Miller, A C Weyand, et al.
The Journal of Biological Chemistry|October 15, 1991
Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand diseaseP A Kroner, K D Friedman, S A Fahs, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 1, 1988
Protein C deficiency. A cause of unusual or unexplained thrombosisD F Tollefson, K D Friedman, R A Marlar, et al.
The Journal of Molecular Diagnostics : JMD|March 29, 2001
A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assayM Ledford, K D Friedman, M J Hessner, et al.
Blood|August 1, 1988
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activityJ Owen, K D Friedman, B A Grossman, et al.
The Journal of Clinical Investigation|June 1, 1987
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activatorJ Owen, K D Friedman, B A Grossman, et al.
Clinical Chemistry|October 24, 2001
Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assayM J Hessner, K D Friedman, K V Voelkerding, et al.
Thrombosis and Haemostasis|June 12, 1999
Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCRM J Hessner, R A Luhm, S L Pearson, et al.
British Journal of Haematology|August 12, 1999
Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriersM J Hessner, D M Dinauer, R A Luhm, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 4, 2014
Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472HJ C Francis, S K Hui, D Mahoney, et al.
Pageof 4